Carcinogenicity of acrolein, crotonaldehyde, and arecoline

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22310%2F21%3A43922699" target="_blank" >RIV/60461373:22310/21:43922699 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S1470204520307270" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1470204520307270</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S1470-2045(20)30727-0" target="_blank" >10.1016/S1470-2045(20)30727-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Carcinogenicity of acrolein, crotonaldehyde, and arecoline

Popis výsledku v původním jazyce

In October–November, 2020, a Working Group of 20 scientists from ten countries met remotely at the invitation of the International Agency for Research on Cancer (IARC) to finalise their evaluations of the carcinogenicity of acrolein, crotonaldehyde, and arecoline. Acrolein was classified as “probably carcinogenic to humans” (Group 2A) on the basis of “sufficient” evidence of carcinogenicity in experimental animals and “strong” mechanistic evidence. Crotonaldehyde and arecoline were classified as “possibly carcinogenic to humans” (Group 2B) on the basis of “strong” mechanistic evidence. For all three agents, the evidence regarding cancer in humans was “inadequate”; no data were available for arecoline, and the few available studies of cancer in humans for acrolein and crotonaldehyde were generally small or uninformative. These assessments will be published in volume 128 of the IARC Monographs.1

Název v anglickém jazyce

Carcinogenicity of acrolein, crotonaldehyde, and arecoline

Popis výsledku anglicky

In October–November, 2020, a Working Group of 20 scientists from ten countries met remotely at the invitation of the International Agency for Research on Cancer (IARC) to finalise their evaluations of the carcinogenicity of acrolein, crotonaldehyde, and arecoline. Acrolein was classified as “probably carcinogenic to humans” (Group 2A) on the basis of “sufficient” evidence of carcinogenicity in experimental animals and “strong” mechanistic evidence. Crotonaldehyde and arecoline were classified as “possibly carcinogenic to humans” (Group 2B) on the basis of “strong” mechanistic evidence. For all three agents, the evidence regarding cancer in humans was “inadequate”; no data were available for arecoline, and the few available studies of cancer in humans for acrolein and crotonaldehyde were generally small or uninformative. These assessments will be published in volume 128 of the IARC Monographs.1

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30304 - Public and environmental health

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

The Lancet Oncology

ISSN

1470-2045

e-ISSN

—

Svazek periodika

22

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

2

Strana od-do

19-20

Kód UT WoS článku

000610553800030

EID výsledku v databázi Scopus

2-s2.0-85099326297